Skip to main content
Signal8

eFFECTOR Therapeutics, Inc. (EFTR)

Sector: Biotechnology

Industry: Biotechnology

eFFECTOR Therapeutics, Inc. logo

eFFECTOR Therapeutics, Inc.

OTC:EFTRHealthcare
$0.0002
CLOSED
Mkt Cap$941
EV-
Float4.67M
O/S4.71M
VOL712 sh
$ Vol$0
RVOL1.86×
Inst Own-
SI0.1%
Net Cash/Sh-
EarningsNov 17 · Today
Dilution
eFFECTOR Therapeutics, Inc. logoOTC:EFTRClosed$0.0002
Historical Data
DateOpenHighLowCloseVolume
Nov 16, 20260.00020.00020.00020.0002712
Nov 5, 20260.00080.00080.00080.0008277
Oct 28, 20260.00020.00020.00020.0002300
Oct 22, 20260.00080.00080.00080.0008500
Oct 20, 20260.00020.00020.00020.0002119
Oct 6, 20260.00080.00080.00020.00021,700
Oct 5, 20260.00080.00080.00080.0008378
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not available
Ratings Distribution
BUY
6
HOLD
0
SELL
0
TOTAL6
Insider Trades
No insider transactions for this companyForeign private issuers and non-reporting entities don't file Form 4/5.
Shareholders
--
Institutional
(1)
--
Insiderⓘ
(0)
--
5%+ Owners
(1)
--
Unattributed (incl. retail)ⓘ
Sources: 13F, 13D/13G
Insiders & Institutional Holders

Top institutional holders

About

eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers.

The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer. Furthermore, eFFECTOR is progressing with Zotatifin, another small-molecule therapeutic designed to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 2 clinical trials, exploring its efficacy in treating different solid tumors. A strategic alliance with Pfizer Inc. supports eFFECTOR's work on developing additional eIF4E inhibitors. Founded in 2012, eFFECTOR Therapeutics, Inc. maintains its operational base in Solana Beach, California.

Key Metrics
Market Cap$941
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 4.71M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryUSUS
IPO DateMar 1, 2021
Shares Outstanding4.71M
Authorized Shares
Float4.67M
52-Week Range
$0.0002$0.0010
$0.0002(0th percentile)
Volume
Average Daily Volume382
712 today vs 382 avg(+86%)

30d Avg

382

60d Avg

1.19K

90d Avg

9.53K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...

eFFECTOR Therapeutics, Inc. (OTC: EFTR) traded at $0.0002 on Nov 16, 2026. 52-week range: $0.0002 to $0.0010. The company is in the Healthcare sector (Biotechnology).